Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNMT | P11086 | 3/20 | 0.44 |
| ▸ | DPP4 | P27487 | 3/20 | 0.41 |
| ▸ | LOXL2 | Q9Y4K0 | 2/20 | 0.35 |
| ▸ | TAAR1 | Q96RJ0 | 6/20 | 0.33 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.33 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.33 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.33 |
| ▸ | HTR2A | P28223 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2616314 | 0.76 | MGLL (0.42) | — | |
| SCHEMBL5570756 | 0.76 | PNMT (0.44) | PNMTDPP4LOXL2TAAR1SLC6A2 | |
| SCHEMBL15247 | 0.73 | PNMT (0.63) | PNMTDPP4LOXL2TAAR1CYP2A6 | |
| SCHEMBL29405036 | 0.73 | PNMT (0.63) | PNMTDPP4LOXL2TAAR1CYP2A6 | |
| SCHEMBL409191 | 0.73 | CYP2A6 (0.31) | CYP2A6 | |
| SCHEMBL30050643 | 0.73 | CYP2A6 (0.31) | CYP2A6 | |
| SCHEMBL11831272 | 0.71 | GABRA1 (0.42) | SLC6A2SLC6A4 | |
| SCHEMBL2662565 | 0.71 | GABRA1 (0.47) | TAAR1SLC6A2SLC6A4SLC6A3CYP2A6 | |
| SCHEMBL9917355 | 0.71 | RIPK1 (0.43) | TAAR1SLC6A2 | |
| Benzene SCHEMBL734438 | 0.70 | DPP4 (0.62) | PNMTDPP4LOXL2TAAR1CYP2A6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8841447-B2 | Process for the preparation of alogliptin | MAPI PHARMA LTD. (IL) | 2014-09-23 | — | — | US | disclosed |
| US-20120029000-A1 | PROCESS FOR THE PREPARATION OF ALOGLIPTIN | MAPI PHARMA LIMITED (IL) | 2012-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120029000-A1 | PROCESS FOR THE PREPARATION OF ALOGLIPTIN | DPP7, DPP4, DPP8 | PNMT 3315/4885DPP4 2/4885LOXL2 2801/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.